Kamal Bouabdallah

2.2k total citations
27 papers, 531 citations indexed

About

Kamal Bouabdallah is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Kamal Bouabdallah has authored 27 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pathology and Forensic Medicine, 15 papers in Oncology and 13 papers in Genetics. Recurrent topics in Kamal Bouabdallah's work include Lymphoma Diagnosis and Treatment (23 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Viral-associated cancers and disorders (7 papers). Kamal Bouabdallah is often cited by papers focused on Lymphoma Diagnosis and Treatment (23 papers), Chronic Lymphocytic Leukemia Research (13 papers) and Viral-associated cancers and disorders (7 papers). Kamal Bouabdallah collaborates with scholars based in France, United States and United Kingdom. Kamal Bouabdallah's co-authors include Gilles Salles, Oliver W. Press, Bruce D. Cheson, Pieternella J. Lugtenburg, Greg Dueck, Marek Trněný, John G. Gribben, Laurie H. Sehn, Jiřı́ Mayer and Günter Fingerle‐Rowson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Kamal Bouabdallah

25 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kamal Bouabdallah France 11 439 350 237 100 76 27 531
Baha Alkuzweny United States 5 369 0.8× 255 0.7× 184 0.8× 95 0.9× 127 1.7× 7 459
Greg Dueck Canada 9 475 1.1× 344 1.0× 229 1.0× 168 1.7× 50 0.7× 13 570
Heidi Nyman Finland 11 501 1.1× 348 1.0× 208 0.9× 189 1.9× 44 0.6× 22 647
Manfred Welslau Germany 7 335 0.8× 306 0.9× 228 1.0× 37 0.4× 49 0.6× 28 501
Abdulwahab J. Al-Tourah Canada 9 525 1.2× 364 1.0× 189 0.8× 150 1.5× 34 0.4× 18 616
Jesse G. Dixon United States 9 323 0.7× 276 0.8× 145 0.6× 49 0.5× 55 0.7× 22 502
Karin E. Summers United Kingdom 9 404 0.9× 280 0.8× 251 1.1× 79 0.8× 67 0.9× 11 608
Ursula Haak Germany 2 413 0.9× 280 0.8× 229 1.0× 51 0.5× 55 0.7× 4 448
Matthew Ku Australia 12 531 1.2× 526 1.5× 262 1.1× 184 1.8× 165 2.2× 47 821

Countries citing papers authored by Kamal Bouabdallah

Since Specialization
Citations

This map shows the geographic impact of Kamal Bouabdallah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamal Bouabdallah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamal Bouabdallah more than expected).

Fields of papers citing papers by Kamal Bouabdallah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamal Bouabdallah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamal Bouabdallah. The network helps show where Kamal Bouabdallah may publish in the future.

Co-authorship network of co-authors of Kamal Bouabdallah

This figure shows the co-authorship network connecting the top 25 collaborators of Kamal Bouabdallah. A scholar is included among the top collaborators of Kamal Bouabdallah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kamal Bouabdallah. Kamal Bouabdallah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gouill, Steven Le, Franck Morschhauser, David Chiron, et al.. (2023). P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.. HemaSphere. 7(S3). e6048802–e6048802. 1 indexed citations
3.
Iyer, Swaminathan P., Deepa Jagadeesh, Eva Domingo‐Doménech, et al.. (2023). P1130: FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032. HemaSphere. 7(S3). e4008899–e4008899. 2 indexed citations
4.
Tessoulin, Benoît, Catherine Thiéblemont, Kamal Bouabdallah, et al.. (2022). Humoral immune depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma. Haematologica. 107(9). 2163–2172. 2 indexed citations
5.
Maerevoet, Marie, Olivier Casasnovas, Guillaume Cartron, et al.. (2022). Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study. Blood. 140(Supplement 1). 6621–6622. 3 indexed citations
6.
Włodarska, Iwona, Olivier Gheysens, Luc Dehaspe, et al.. (2021). The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU Leuven and LYSA study on cell-free DNA. Blood Advances. 5(7). 1991–2002. 18 indexed citations
7.
Patel, Krish, Jean‐Marie Michot, Asher Chanan‐Khan, et al.. (2021). Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 138(Supplement 1). 2494–2494. 19 indexed citations
8.
Tessoulin, Benoît, Kamal Bouabdallah, Barbara Burroni, et al.. (2020). Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA. Annals of Hematology. 99(8). 1771–1778. 9 indexed citations
9.
10.
Truemper, Lorenz, Marita Ziepert, Kamal Bouabdallah, et al.. (2019). First-line therapy of T-cell lymphoma: Allogeneic or autologous transplantation for consolidation—Final results of the AATT study.. Journal of Clinical Oncology. 37(15_suppl). 7503–7503. 10 indexed citations
11.
Cheson, Bruce D., Neil Chua, Jiřı́ Mayer, et al.. (2018). Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. Journal of Clinical Oncology. 36(22). 2259–2266. 100 indexed citations
12.
Gouill, Steven Le, Andrew Davies, Kamal Bouabdallah, David Chiron, & Simon Rule. (2016). OAsis: An international phase I trial of obinutuzumab, venetoclax plus ibrutinib in relapsed/refractory mantle cell lymphoma.. Journal of Clinical Oncology. 34(15_suppl). TPS7583–TPS7583. 2 indexed citations
13.
Witzig, Thomas E., Kensei Tobinai, Luigi Rigacci, et al.. (2016). PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 34(15_suppl). 7506–7506. 11 indexed citations
14.
15.
16.
Casasnovas, Olivier, Salim Kanoun, Ṭal Ilan, et al.. (2016). Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial.. Journal of Clinical Oncology. 34(15_suppl). 7509–7509. 14 indexed citations
17.
Schmitz, Norbert, Maike Nickelsen, Bettina Altmann, et al.. (2015). Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: Results of the interim analysis of the AATT trial.. Journal of Clinical Oncology. 18 indexed citations
18.
Sehn, Laurie H., Neil Chua, Jiřı́ Mayer, et al.. (2015). GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.. Journal of Clinical Oncology. 33(18_suppl). LBA8502–LBA8502. 15 indexed citations
19.
Morschhauser, Franck, Kamal Bouabdallah, Stephan Stilgenbauer, et al.. (2014). Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Blood. 124(21). 3067–3067. 17 indexed citations
20.
Lin, Tongyu, Jun Zhu, Kamal Bouabdallah, et al.. (2012). PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 30(15_suppl). TPS8118–TPS8118. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Baha Alkuzweny Breakdown of academic impact, for papers by Greg Dueck Breakdown of academic impact, for papers by Heidi Nyman Breakdown of academic impact, for papers by Manfred Welslau Breakdown of academic impact, for papers by Abdulwahab J. Al-Tourah Breakdown of academic impact, for papers by Jesse G. Dixon Breakdown of academic impact, for papers by Karin E. Summers Breakdown of academic impact, for papers by Ursula Haak Breakdown of academic impact, for papers by Matthew Ku
Rankless by CCL
2026